News

Symbicort Turbuhaler is a twice-daily treatment for adult bronchial asthma combining budesonide, an inhaled corticosteroid (one dose containing 160µg) and formoterol fumarate dihydrate, a rapid and long acting

Reportedly, based on the investigation, McNeil Consumer Healthcare has determined that the reported uncharacteristic smell is caused by the presence of trace amounts of a chemical called 2,4,6-tribromoanisole

The company said that the new certificate will be valid until November 2014. Jiangbo has another GMP certified factory to produce traditional chinese medicines in tablets, granules, pills,

Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours

Novartis also receives certain option rights in cardiovascular and oncology product applications, and rights to use Proteus technologies in its clinical development of pharmaceutical products. Under the terms

Jean-Jacques Bienaime, chief executive officer of BioMarin, said: “BMN 195 has been shown to upregulate utrophin levels in human muscle cells, as a means of augmenting muscle function.

Endo is expected to have full ownership of the compounds developed under the collaboration with exclusive worldwide rights, and will fund all subsequent drug development and commercialisation activities.

Kinaxo’s phosphoproteomics platform, PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using the quantitative mass spectrometry, up to

In parallel, Biovail Laboratories International, a subsidiary of Biovail, and MedGenesis have concluded an agreement to collaborate on the development of GDNF in parkinson’s disease and potentially other